CVS Health Co. (NYSE:CVS) Shares Sold by Oliver Lagore Vanvalin Investment Group

Oliver Lagore Vanvalin Investment Group decreased its position in shares of CVS Health Co. (NYSE:CVSFree Report) by 70.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 366 shares of the pharmacy operator’s stock after selling 872 shares during the period. Oliver Lagore Vanvalin Investment Group’s holdings in CVS Health were worth $29,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Cantor Fitzgerald Investment Advisor L.P boosted its stake in shares of CVS Health by 92.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 377,875 shares of the pharmacy operator’s stock valued at $38,245,000 after buying an additional 181,966 shares in the last quarter. United Bank boosted its stake in shares of CVS Health by 7.2% in the first quarter. United Bank now owns 18,658 shares of the pharmacy operator’s stock valued at $1,888,000 after buying an additional 1,260 shares in the last quarter. Loomis Sayles & Co. L P boosted its stake in shares of CVS Health by 4,063.8% in the first quarter. Loomis Sayles & Co. L P now owns 12,075 shares of the pharmacy operator’s stock valued at $1,222,000 after buying an additional 11,785 shares in the last quarter. Zions Bancorporation N.A. boosted its position in CVS Health by 116.9% during the first quarter. Zions Bancorporation N.A. now owns 2,572 shares of the pharmacy operator’s stock worth $260,000 after purchasing an additional 1,386 shares in the last quarter. Finally, Ergoteles LLC purchased a new stake in CVS Health during the first quarter worth $1,551,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on CVS. HSBC began coverage on CVS Health in a research report on Friday, December 22nd. They set a “buy” rating and a $94.00 target price on the stock. Barclays began coverage on CVS Health in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $78.00 target price on the stock. StockNews.com downgraded CVS Health from a “buy” rating to a “hold” rating in a research report on Thursday, February 15th. SVB Leerink assumed coverage on CVS Health in a research report on Monday, February 26th. They issued an “outperform” rating and a $88.00 price objective on the stock. Finally, Royal Bank of Canada reduced their price objective on CVS Health from $86.00 to $84.00 and set an “outperform” rating on the stock in a research report on Thursday, February 8th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $89.44.

View Our Latest Report on CVS Health

Insider Activity

In related news, EVP Prem S. Shah sold 29,473 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $76.95, for a total value of $2,267,947.35. Following the completion of the transaction, the executive vice president now owns 39,765 shares of the company’s stock, valued at $3,059,916.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.24% of the company’s stock.

CVS Health Stock Performance

Shares of NYSE:CVS opened at $69.39 on Friday. The firm has a market capitalization of $87.46 billion, a PE ratio of 10.74, a P/E/G ratio of 0.91 and a beta of 0.52. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.86 and a quick ratio of 0.63. The business has a 50-day moving average of $75.42 and a two-hundred day moving average of $73.70. CVS Health Co. has a 12 month low of $64.41 and a 12 month high of $83.25.

CVS Health (NYSE:CVSGet Free Report) last posted its earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.11. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The business had revenue of $93.81 billion during the quarter, compared to analyst estimates of $90.58 billion. During the same quarter last year, the firm earned $1.99 earnings per share. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. As a group, research analysts forecast that CVS Health Co. will post 8.32 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd will be paid a $0.665 dividend. The ex-dividend date of this dividend is Friday, April 19th. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.83%. CVS Health’s dividend payout ratio (DPR) is currently 41.18%.

About CVS Health

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

See Also

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSFree Report).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.